

Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028

<https://marketpublishers.com/r/BDCD1EDA43D0EN.html>

Date: September 2023

Pages: 324

Price: US\$ 4,950.00 (Single User License)

ID: BDCD1EDA43D0EN

Abstracts

The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing partnerships and collaborations between pharmaceutical companies and biologics contract manufacturers. For instance, In January 2023, Catalent (US) entered into an agreement with Sarepta Therapeutics, Inc. (US) for manufacturing of Sarepta's most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001) for the treatment of Duchenne muscular dystrophy. Similarly, In December 2022, Merck KGaA (Germany) and Synplogen (Japan) entered into an agreement to accelerate the development and manufacturing of viral vector-based gene therapy applications.

"The monoclonal antibodies segment accounted for the largest share by molecule type during the forecast period."

In 2022, the monoclonal antibodies segment accounted for the largest share by molecules in the global biotechnology contract manufacturing market. The large share of this segment is attributed to the rising prevalence of diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in the clinical pipeline.

“Europe: The second largest region in the biotechnology contract manufacturing market”

Europe accounted for the second-largest market for biotechnology contract manufacturing market after North America. The European biotechnology contract manufacturing market has experienced substantial growth in recent years, driven by various factors such as increasing investments for the development of biologics such as monoclonal antibodies and cell & gene therapies and biomanufacturing capacity expansions. Europe is at the forefront of developing and adopting emerging technologies in the field of biotechnology contract manufacturing market. In March 2023, Lonza completed its cGMP clinical and commercial manufacturing site, which is dedicated to large-scale commercial drug product manufacturing.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side - 70% and Demand Side - 30%

By Designation: Managers - 45%, CXO and Directors - 30%, and Executives - 25%

By Region: North America - 40%, Europe - 25%, Asia-Pacific - 20%, Latin America - 10% and Middle East & Africa - 5%

List of Companies Profiled in the Report:

Lonza (Switzerland)

Thermo Fisher Scientific Inc. (US)

Catalent, Inc. (US)

Samsung Biologics (South Korea)

WuXi Biologics (China)

Boehringer Ingelheim International GmbH (Germany)

FUJIFILM Holdings Corporation (Japan)

AbbVie, Inc. (US)

Eurofins Scientific (Luxembourg)

GenScript Biotech Corporation (US)

AGC, Inc. (Japan)

Merck KGaA (Germany)

JSR Corporation (Japan)

Stelis (India)

Recipharm AB (Sweden)

Emergent (US)

Shanghai Fosun Pharmaceutical Co., Ltd. (China)

LOTTE BIOLOGICS (South Korea)

Hepalink Group (China)

Curia Global, Inc. (US)

JRS Pharma (Germany)

MINAPHARM Pharmaceuticals (Egypt)

Rentschler Biopharma SE (Germany)

Avid Bioservices, Inc. (US)

Abzena Ltd. (US)

Polyplus Transfection (Germany)

Midas Pharma GmbH (Germany)

MabPlex International Co., Ltd. (China)

Asahi Kasei Corporation (Japan)

Research Coverage:

This report provides a detailed picture of the biotechnology contract manufacturing market. It aims to estimate the size and future growth potential of the market across different segments such as the service, type, scale of operation, source, molecule type, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for biologics & biosimilars, Increased biologics outsourcing trend among biopharmaceutical companies, Increased focus on personalized medicine, Increasing partnerships and collaborations between pharmaceutical companies and biologics CDMOs), restraints (intellectual property rights issues), opportunities (Rising demand for cell & gene therapy, biologics contract manufacturing market expansions in emerging countries, expansion of biologics manufacturing capacities by CMOs, strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.

Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the biotechnology contract manufacturing

market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biotechnology contract manufacturing market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), WuXi Biologics (China), AbbVie, Inc. (US), and others in the market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION AND SCOPE
 - 1.2.1 INCLUSIONS AND EXCLUSIONS
 - 1.2.2 MARKETS COVERED
 - 1.2.3 YEARS CONSIDERED
- 1.3 CURRENCY
- 1.4 STAKEHOLDERS
- 1.5 LIMITATIONS
- 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 1 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
 - FIGURE 2 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
- 2.2 MARKET SIZE ESTIMATION
 - FIGURE 3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
 - FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2022
 - FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022
 - 2.2.1 INSIGHTS FROM PRIMARIES
 - FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
 - FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
- 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
 - FIGURE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
 - FIGURE 9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
 - FIGURE 10 DATA TRIANGULATION METHODOLOGY

2.5 RESEARCH ASSUMPTIONS

2.6 RISK ANALYSIS

2.7 RECESSION IMPACT ANALYSIS

TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)

TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)

TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)

3 EXECUTIVE SUMMARY

FIGURE 11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION)

FIGURE 12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 13 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023 VS. 2028 (USD MILLION)

FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET

4 PREMIUM INSIGHTS

4.1 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET OVERVIEW

FIGURE 15 RISING APPROVALS OF BIOLOGICS TO DRIVE MARKET

4.2 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY SCALE OF OPERATION & COUNTRY (2022)

FIGURE 16 COMMERCIAL OPERATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022

4.3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028

FIGURE 17 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028

4.4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028

4.5 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 20 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

TABLE 4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS

5.2.1 DRIVERS

5.2.1.1 Rising demand for biologics and biosimilars

FIGURE 21 NUMBER OF APPROVED BIOLOGICS, 2015–2022

FIGURE 22 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015–2022

5.2.1.2 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies

5.2.1.3 Growing focus on personalized medicine

FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2022

5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs

5.2.1.5 Advancements in manufacturing technologies

5.2.2 RESTRAINTS

5.2.2.1 Intellectual property rights issues

5.2.3 OPPORTUNITIES

5.2.3.1 Rising demand for cell and gene therapies

TABLE 5 LIST OF EXPANSIONS BY TOP COMPANIES

5.2.3.2 Significant growth opportunities offered by emerging countries

5.2.3.3 Expansion of biologics manufacturing capacities by CMOs

5.2.3.4 Strong emphasis on drug development

TABLE 6 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY

5.2.4 CHALLENGES

5.2.4.1 Complying with regulatory reforms

5.3 VALUE CHAIN ANALYSIS

FIGURE 24 VALUE CHAIN ANALYSIS OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: MANUFACTURING AND DISTRIBUTION PHASES
ADD MAXIMUM VALUE

5.4 ECOSYSTEM ANALYSIS

FIGURE 25 ECOSYSTEM ANALYSIS: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET

TABLE 7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM**5.5 PORTER'S FIVE FORCES ANALYSIS****TABLE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS****5.5.1 THREAT OF NEW ENTRANTS****5.5.2 THREAT OF SUBSTITUTES****5.5.3 BARGAINING POWER OF SUPPLIERS****5.5.4 BARGAINING POWER OF BUYERS****5.5.5 INTENSITY OF COMPETITIVE RIVALRY****5.6 TECHNOLOGY ANALYSIS****5.7 REGULATORY ANALYSIS****5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS****TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS****TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS****TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS****TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS****TABLE 13 REGULATORY SCENARIOS ACROSS DIFFERENT COUNTRIES/REGIONS****5.8 KEY CONFERENCES AND EVENTS IN 2023–2024****TABLE 14 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS****5.9 KEY STAKEHOLDERS AND BUYING CRITERIA****5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS****FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOTECHNOLOGY CMO SERVICES****5.9.2 BUYING CRITERIA****FIGURE 27 KEY BUYING CRITERIA FOR END USERS****5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS****6 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE****6.1 INTRODUCTION****TABLE 15 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY**

SERVICE, 2021–2028 (USD MILLION)

6.2 MANUFACTURING

6.2.1 SHIFT TOWARD SINGLE-USE TECHNOLOGY TO DRIVE MARKET

TABLE 16 BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 17 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 18 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 19 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 20 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

6.3 FORMULATION & FILL-FINISH

6.3.1 MOST CRITICAL ASPECT OF BIOLOGICS MANUFACTURING

TABLE 21 BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 22 NORTH AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 23 EUROPE: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 24 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 25 LATIN AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

6.4 PACKAGING & LABELING

6.4.1 FINAL CHECKPOINT BEFORE PRODUCT REACHES PATIENT

TABLE 26 BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 27 NORTH AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 28 EUROPE: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 29 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 30 LATIN AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

6.5 OTHER SERVICES

TABLE 31 OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES

MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 32 NORTH AMERICA: OTHER BIOTECHNOLOGY CONTRACT

MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 33 EUROPE: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING

SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 34 ASIA PACIFIC: OTHER BIOTECHNOLOGY CONTRACT

MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 35 LATIN AMERICA: OTHER BIOTECHNOLOGY CONTRACT

MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE

7.1 INTRODUCTION

TABLE 36 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING

7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET

TABLE 37 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 38 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 39 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 40 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 41 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING

7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY PROMPTED SHIFT TOWARD CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS

TABLE 42 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 43 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 44 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 45 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 46 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

8.1 INTRODUCTION

TABLE 47 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

8.2 COMMERCIAL OPERATIONS

8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH

TABLE 48 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 49 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 50 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 51 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 52 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

8.3 CLINICAL OPERATIONS

8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET

TABLE 53 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)

TABLE 54 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 55 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 56 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 57 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)

9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE

9.1 INTRODUCTION

TABLE 58 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

9.2 MAMMALIAN EXPRESSION SYSTEMS

9.2.1 VERSATILE THERAPEUTIC DIVERSITY TO DRIVE MARKET

TABLE 59 TYPES OF MAMMALIAN EXPRESSION SYSTEMS

TABLE 60 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION)

TABLE 61 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 62 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 63 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 64 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

9.3 NON-MAMMALIAN EXPRESSION SYSTEMS

9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH

TABLE 65 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS

TABLE 66 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021–2028 (USD MILLION)

TABLE 67 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 68 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 69 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 70 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2021–2028 (USD MILLION)

10 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE

10.1 INTRODUCTION

TABLE 71 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
MOLECULE TYPE, 2021–2028 (USD MILLION)

10.2 MONOCLONAL ANTIBODIES

10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET

FIGURE 28 NUMBER OF APPROVED MONOCLONAL ANTIBODIES, 2010–2022

TABLE 72 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR
MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 73 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 74 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 75 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 76 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD
MILLION)

10.3 CELL & GENE THERAPIES

10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET

TABLE 77 FDA-APPROVED CAR T-CELL THERAPIES

TABLE 78 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL
& GENE THERAPIES, BY REGION, 2021–2028 (USD MILLION)

TABLE 79 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 80 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 81 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 82 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION)

10.4 ANTIBODY-DRUG CONJUGATES

10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH

TABLE 83 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2021–2028 (USD MILLION)

TABLE 84 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 85 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 86 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 87 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021–2028 (USD MILLION)

10.5 VACCINES

10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET

TABLE 88 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)

TABLE 89 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)

TABLE 90 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 91 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 92 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 93 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)

10.6 THERAPEUTIC PEPTIDES & PROTEINS

10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH

TABLE 94 EXAMPLES OF PEPTIDE THERAPEUTICS

TABLE 95 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE

TABLE 96 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2021–2028 (USD MILLION)

TABLE 97 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 98 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 99 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028
(USD MILLION)

TABLE 100 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021–2028
(USD MILLION)

10.7 OTHER MOLECULE TYPES

TABLE 101 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR
OTHER MOLECULE TYPES, BY REGION, 2021–2028 (USD MILLION)

TABLE 102 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 103 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 104 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021–2028 (USD
MILLION)

11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA

11.1 INTRODUCTION

TABLE 106 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
THERAPEUTIC AREA, 2021–2028 (USD MILLION)

11.2 ONCOLOGY

11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY
TO DRIVE MARKET

TABLE 107 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR
ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 108 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 109 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 110 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 111 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

11.3 AUTOIMMUNE DISEASES

11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET

TABLE 112 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 113 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 114 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 115 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 116 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

11.4 METABOLIC DISEASES

11.4.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS

TABLE 117 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 118 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 119 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 120 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 121 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

11.5 CARDIOVASCULAR DISEASES

11.5.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH

TABLE 122 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 123 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 124 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 125 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 126 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

11.6 NEUROLOGY

11.6.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
TABLE 127 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)

TABLE 128 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 129 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 130 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 131 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION)

11.7 INFECTIOUS DISEASES

11.7.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
TABLE 132 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)

TABLE 133 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 134 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 135 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 136 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)

11.8 OTHER THERAPEUTIC AREAS

TABLE 137 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)

TABLE 138 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 139 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET

FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD
MILLION)

TABLE 141 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD
MILLION)

12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION

12.1 INTRODUCTION

TABLE 142 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
REGION, 2021–2028 (USD MILLION)

12.2 NORTH AMERICA

FIGURE 29 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET SNAPSHOT

TABLE 143 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 144 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 145 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 146 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 147 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 148 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 149 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.2.1 US

12.2.1.1 Presence of large number of FDA-approved manufacturing facilities to favor
market growth

TABLE 150 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
SERVICE, 2021–2028 (USD MILLION)

TABLE 151 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
TYPE, 2021–2028 (USD MILLION)

TABLE 152 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY
SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 153 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 154 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 155 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.2.2 CANADA

12.2.2.1 Rising government funding for drug development to support market growth

TABLE 156 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 157 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 158 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 159 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 160 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 161 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.2.3 RECESSION IMPACT

12.3 EUROPE

TABLE 162 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 163 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 164 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 165 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 166 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 167 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 168 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.1 GERMANY

12.3.1.1 Rapidly growing pharmaceutical market to drive market

TABLE 169 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 170 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 171 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 172 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 173 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 174 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.2 UK

12.3.2.1 Rising investments in drug development to favor market growth

TABLE 175 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 176 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 177 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 178 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 179 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 180 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.3 FRANCE

12.3.3.1 Availability of funds from government and private organizations for domestic drug development to support market growth

TABLE 181 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 182 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 183 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 184 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 185 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 186 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,

BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)**12.3.4 ITALY**

12.3.4.1 Rising commercial drug development pipeline to drive market

TABLE 187 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 188 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 189 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 190 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 191 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 192 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.5 SPAIN

12.3.5.1 Rising R&D expenditure to propel market

TABLE 193 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 194 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 195 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 196 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 197 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 198 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.6 REST OF EUROPE

TABLE 199 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 200 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 201 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 202 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 203 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING

MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 204 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.3.7 RECESSION IMPACT

12.4 ASIA PACIFIC

FIGURE 30 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET SNAPSHOT

TABLE 205 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 206 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 207 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 208 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 209 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 210 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 211 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING
MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.1 CHINA

12.4.1.1 Low manufacturing cost and high demand for medicines to favor market
growth

TABLE 212 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY SERVICE, 2021–2028 (USD MILLION)

TABLE 213 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY TYPE, 2021–2028 (USD MILLION)

TABLE 214 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 215 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY SOURCE, 2021–2028 (USD MILLION)

TABLE 216 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 217 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,
BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.2 JAPAN

12.4.2.1 Growing demand for biosimilars to drive growth

TABLE 218 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET,

BY SERVICE, 2021–2028 (USD MILLION)

TABLE 219 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 220 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 221 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 222 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 223 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.3 SOUTH KOREA

12.4.3.1 Increasing R&D activities for drug development to drive market

TABLE 224 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 225 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 226 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 227 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 228 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 229 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.4 INDIA

12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth

TABLE 230 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 231 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 232 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 233 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 234 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 235 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY

THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.5 REST OF ASIA PACIFIC

TABLE 236 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 237 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 238 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 239 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 240 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 241 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.4.6 RECESSION IMPACT

12.5 LATIN AMERICA

TABLE 242 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 243 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 244 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 245 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 246 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 247 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 248 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.5.1 BRAZIL

12.5.1.1 Growing pharmaceutical industry to drive market

TABLE 249 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 250 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 251 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 252 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 253 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 254 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.5.2 REST OF LATIN AMERICA

TABLE 255 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 256 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 257 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 258 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 259 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 260 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.5.3 RECESSION IMPACT

12.6 MIDDLE EAST & AFRICA

12.6.1 GROWING PHARMACEUTICALS INDUSTRY TO SUPPORT MARKET GROWTH

TABLE 261 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD MILLION)

TABLE 262 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 263 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)

TABLE 264 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021–2028 (USD MILLION)

TABLE 265 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021–2028 (USD MILLION)

TABLE 266 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)

12.6.2 RECESSION IMPACT

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION

FIGURE 31 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET:
STRATEGIES ADOPTED BY KEY PLAYERS

13.2 REVENUE SHARE ANALYSIS

FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022

13.3 MARKET SHARE ANALYSIS

FIGURE 33 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE
ANALYSIS OF KEY PLAYERS, 2022

TABLE 267 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEGREE
OF COMPETITION

13.4 COMPANY EVALUATION MATRIX

13.4.1 STARS

13.4.2 EMERGING LEADERS

13.4.3 PERVASIVE PLAYERS

13.4.4 PARTICIPANTS

FIGURE 34 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET:
COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022

13.5 COMPETITIVE BENCHMARKING

13.5.1 COMPANY FOOTPRINT ANALYSIS

TABLE 268 COMPANY FOOTPRINT ANALYSIS

13.5.2 COMPANY FOOTPRINT ANALYSIS, BY MOLECULE TYPE

TABLE 269 MOLECULE TYPE FOOTPRINT ANALYSIS OF COMPANIES

13.5.3 COMPANY FOOTPRINT ANALYSIS, BY REGION

TABLE 270 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES

13.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES

13.6.1 PROGRESSIVE COMPANIES

13.6.2 STARTING BLOCKS

13.6.3 RESPONSIVE COMPANIES

13.6.4 DYNAMIC COMPANIES

FIGURE 35 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET:
COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022

13.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS

TABLE 271 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED
LIST OF KEY STARTUP/SME PLAYERS

TABLE 272 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET:
COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS

13.8 COMPETITIVE SCENARIO AND TRENDS

13.8.1 DEALS

TABLE 273 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2020–JULY 2023

13.8.2 OTHER DEVELOPMENTS

TABLE 274 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JULY 2023

14 COMPANY PROFILES

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

14.1 KEY PLAYERS

14.1.1 LONZA

TABLE 275 LONZA: BUSINESS OVERVIEW

FIGURE 36 LONZA: COMPANY SNAPSHOT (2022)

14.1.2 THERMO FISHER SCIENTIFIC INC.

TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW

FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)

14.1.3 WUXI BIOLOGICS

TABLE 277 WUXI BIOLOGICS: BUSINESS OVERVIEW

FIGURE 38 WUXI BIOLOGICS: COMPANY SNAPSHOT (2022)

14.1.4 CATALENT, INC.

TABLE 278 CATALENT, INC.: BUSINESS OVERVIEW

FIGURE 39 CATALENT, INC.: COMPANY SNAPSHOT (2022)

14.1.5 SAMSUNG BIOLOGICS

TABLE 279 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW

FIGURE 40 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)

14.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

TABLE 280 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW

FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)

14.1.7 FUJIFILM HOLDINGS CORPORATION

TABLE 281 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW

FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)

14.1.8 ABBVIE INC.

TABLE 282 ABBVIE INC.: BUSINESS OVERVIEW

FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2022)

14.1.9 EUROFINS SCIENTIFIC

TABLE 283 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW

FIGURE 44 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)

14.1.10 GENSCRIPT BIOTECH CORPORATION

TABLE 284 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW

FIGURE 45 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)

14.1.11 AGC INC.

TABLE 285 AGC INC.: BUSINESS OVERVIEW

FIGURE 46 AGC INC.: COMPANY SNAPSHOT (2022)

14.1.12 MERCK KGAA

TABLE 286 MERCK KGAA: BUSINESS OVERVIEW

FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)

14.1.13 JSR CORPORATION

TABLE 287 JSR CORPORATION: BUSINESS OVERVIEW

FIGURE 48 JSR CORPORATION: COMPANY SNAPSHOT (2022)

14.2 OTHER PLAYERS

14.2.1 STELIS

14.2.2 RECIPHARM AB

14.2.3 EMERGENT

14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.

14.2.5 LOTTE BIOLOGICS

14.2.6 HEPALINK GROUP

14.2.7 CURIA GLOBAL, INC.

14.2.8 JRS PHARMA

14.2.9 MINAPHARM PHARMACEUTICALS

14.2.10 RENTSCHLER BIOPHARMA SE

14.2.11 AVID BIOSERVICES, INC.

14.2.12 ABZENA LTD.

14.2.13 POLYPLUS TRANSFECTION

14.2.14 MIDAS PHARMA GMBH

14.2.15 MABPLEX INTERNATIONAL CO., LTD.

14.2.16 ASAHI KASEI CORPORATION

Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats) might not be captured in case of unlisted companies.

15 APPENDIX

15.1 DISCUSSION GUIDE

15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

15.3 CUSTOMIZATION OPTIONS

15.4 RELATED REPORTS

15.5 AUTHOR DETAILS

I would like to order

Product name: Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028

Product link: <https://marketpublishers.com/r/BDCD1EDA43D0EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDCD1EDA43D0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970